@jonathanloree
Account based inCanada
About this account
- Account based in
- Canada
- Connected via
- Canada App Store
Account-level information from X, not a live location or the device used for a specific post.
GI Medical Oncologist at BC Cancer, Associate Professor at The University of British Columbia, Senior Investigator at the Canadian Cancer Trials Group (CCTG)
Vancouver, British Columbia
Joined March 2014
- Tweets935
- Following329
- Followers850
- Likes2.4K
Jonathan Loree retweeted
Have you ever wondered what the outcomes are of patients with small bowel NETs and liver mets following cytoreductive hepatectomy if there is co-existing carcinoid heart disease (CHD)? Are the outcomes different in the CHD population when compared to those without CHD?
As it seems, probably not. In this retrospective study done at Mayo Clinic, the outcomes of 311 patients were analyzed. 163 had nonfunctional NETs, 110 had carcinoid syndrome (CS) and 38 had CS + CHD. Median overall survival after debulking was very similar, 12.5 vs. 9.1 vs 11.4 years.
With optimal cardiac management, cytoreductive hepatectomy in CHD is feasible and provides long-term survival comparable to patients without CHD.
Careful multidisciplinary evaluation and management is key.
onlinelibrary.wiley.com/doi/…
@MayoCancerCare @MayoClinicSurg
Jonathan Loree retweeted
This is an absolutely outstanding review on the management of patients with metastatic gastric cancer.
I may have posted about this review before but it is so good that it deserves another round of applause... Thanks @KlempnerSam @YJanjigianMD @amalsargsyan and all the other co-authors I could not find on X...
Sorry AI, I love you but you are just not there yet. True content experts writing a practical review still beat you easily.
This should be a required read for all who take care of patients with gastric cancer.
nature.com/articles/s41571-0…
Jonathan Loree retweeted
#CCTG2026 @CDNCancerTrials 🇨🇦
A pleasure to host @JeanneTie to our CCTG Annual Meeting to advance our strong history of trials collaboration with @GICancer #formerlyAGITG 🇦🇺 🇳🇿
Special shout out to her #ILoveCanada earrings! ❤️
Jonathan Loree retweeted
🌐 BATTMAN trial begins in MSS metastatic colorectal cancer
On April 1, 2026, Agenus announced that the first patient has been enrolled in the phase III BATTMAN trial.
BATTMAN is a global, randomized phase III study evaluating botensilimab + balstilimab vs best supportive care in patients with refractory, unresectable MSS metastatic colorectal cancer.
The trial is being conducted across international sites and represents a potential registrational study in this setting.
@Agenus_Bio @oncodaily @jonathanloree @garo_armen
📎oncodaily.com/oncolibrary/ba…
#OncoDaily #GIOncology #ColorectalCancer #Immunotherapy #ClinicalTrials
Jonathan Loree retweeted
Sharing the final publication and schema! @NANETS1 Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors doi.org/10.1530/ERC-25-0303
Jonathan Loree retweeted
@OHSUKnight study showed standard dose (35mg/m2 bid) Trifluridine (Lonsurf) wk 1, 3 and 5 of #radiation for stage 2/3 #rectalcancer was safe with TNT. 56% of patients did Watch and Wait.
➡️New option for patients with 5-FU toxicity/contraindications❓
clinical-colorectal-cancer.c…
Jonathan Loree retweeted
Check out our new @NANETS Guidelines for Stage I-III Rectal NETs! Big updates in:
- staging with MRI & PET Dotatate
- advanced excision for < vs. >10 mm tumors
- management of R1 excision
- surgery
- follow-up
@AmanChauhanMD @OncoThor @FlavioRochaMD
doi.org/10.1530/ERC-25-0303
Congrats @RobertoFedrigo on your new manuscript on treatment attrition in NETs! Shows how many patients never reach later lines of therapy. Important context as we interpret NETTER-2 and debate earlier PRRT use.
sciencedirect.com/science/ar…
#NETs #PRRT #NETTER2 #oncology
How would you prefer to be screened for colorectal cancer? 🩺
We’re surveying people to better understand preferences — including whether blood-based tests could reduce barriers. Please retweet &
Share your voice: rc.bcchr.ca/redcap/surveys/?…
@BCCancer @bccancerfdn @coloncanada
Jonathan Loree retweeted
Applications are being accepted for the #CCTG 2026-2027 New Investigator Cancer Trials Practicum - a training program that enables the brightest new Canadian oncology researchers to acquire training & experience in clinical trial conduct. How to apply: buff.ly/pVU9ts3
Jonathan Loree retweeted
AI meets digital pathology! 🔬 We used machine learning on whole-slide images of neuroendocrine tumors to classify grade, differentiation & prognosis.
✍ Authors: Amir Hadjifaradji et al. @jonathanloree @BCCancer @bccancerfdn
🌻 Read in @Cancers_MDPI
mdpi.com/2072-6694/17/18/299…
A nice retrospective study looking at chemo doublets in biliary tract cancer. "FOLFOX Versus FOLFIRI as Second‐Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study - Pircher - 2026" onlinelibrary.wiley.com/doi/…
Jonathan Loree retweeted
The "Big Bang" of cancer evolution: for colon cancer, evidence that immune evasion occurs very early
nature.com/articles/s41588-0…
Jonathan Loree retweeted
So Dill started this to help Canadian patients...
and once he got the platform running for Canada...
he made it global. In a weekend.
Oh, Canada!
@ccranorg @coloncanada
@CAMO_ACOM @CDNCancerTrials @uoftmedicine @Sunnybrook @BCCancer
@GillSharlene @jonathanloree @ocall0
Results from DYNAMIC-III RCT of ctDNA-guided adjuvant tx in stage III colon cancer in Nature Med.
🙏 to pts, providers & @JeanneTie
🇨🇦🇦🇺 @CDNCancerTrials & @GICancer Collab
#ESMO2025 Presidential | Supported by @CIHR_IRSC & @cancersociety in 🇨🇦
🔗 rdcu.be/eLTj8
Jonathan Loree retweeted
Excited to be at the #ESMO25 launch of the phase 3 @CDNCancerTrials 🇨🇦 #BATTMAN CO.33
BOT/BAL vs BSC in refractory MSS mCRC #unmetneed #trialsthatmatter
Congrats to @jonathanloree 🙌
@ocall0 @Agenus_Bio
@GICancer @JeanneTie
Let’s get this done! 🇨🇦 🇦🇺 🇫🇷
@coloncanada @ccranorg
@OncoAlert
Jonathan Loree retweeted
Dr Booth presenting the #CCTG #CO21 #CHALLENGE trial to the GI tumours group at #ESMO2025 - the study was recently published in #NEJM nejm.org/doi/10.1056/NEJMoa2…
Jonathan Loree retweeted
#ESMO25
@CDNCancerTrials
GI disease site is in the house! 🙌
Looking forward to the 🌟 Presidential session later today for DYNAMIC III/CCTG CO.29 🎤 🇨🇦 🇦🇺
📌 ctDNA guided ACT de-escalation in stage3 CC @JeanneTie @jonathanloree
@OncoAlert
@GICancer
#ESMOAmbassadors
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Jonathan Loree retweeted
Exciting science and clinical efficacy in this @MDAndersonNews team science study led by @VanMorrisMD In Cancer Cell.
Triple therapy with IO led to durable responses in BRAF V600E MSS colorectal cancer, showing promise. Randomized study ongoing. #crcsm
cell.com/cancer-cell/fulltex…
